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ABSTRACT
Background. Human papillomavirus (HPV) vaccination is rec-
ommended for all adolescents aged 11 to 12 years, but coverage 
in Kansas is exceptionally poor. To understand local coverage, re-
ceipt of the 3-dose HPV vaccine series among pediatric patients at 
the University of Kansas Medical Center (KUMC) was evaluated.
Methods. All patients aged 11 to 12 years who were seen by a 
KUMC primary care provider (family medicine and pediatrics) 
in 2013 were included in the retrospective chart review. Records 
were reviewed through December 31, 2014 to capture the num-
ber of HPV doses received, and receipt of other recommended 
vaccines (tetanus-diphtheria-pertussis and meningococcal con-
jugate). Pearson’s chi-squared tests were used to evaluate rela-
tionships between HPV vaccination and patient characteristics.
Results. Of the 261 eligible females and 243 eligible males, 71.2% 
received ≥ 1 HPV vaccine dose, 55.2% received ≥ 2 doses, and 
39.3% completed the HPV vaccine series (3 doses). Although vac-
cine initiation was slightly lower in males compared to females 
(67.1% vs. 75.1%, p = 0.047), no difference in vaccine completion 
was seen between males and females (37.0% vs. 41.7%,  p = 0.319). 
Over 80% of patients received other concurrently recommended 
vaccines (Tdap: 81.7%, meningococcal: 81.3%). HPV series com-
pletion occurred more often among Spanish-speaking females 
compared to English-speaking females (59.5% vs 37.7%; p < 0.01). 
Conclusions. The proportion of adolescents who received the 
HPV vaccination at KUMC is substantially higher than nation-
al and state estimates, but there is room for improvement for 
both initiation and series completion. KS J Med 2016;9(1):1-5.
INTRODUCTION
  There are approximately 14 million new human papilloma-
virus (HPV) infections in the United States annually, making it 
the most common sexually transmitted infection in the country.1 
While the majority of HPV infections clear the body with no 
adverse outcomes, HPV also leads to an estimated 26,000 new 
cases of cancer every year in the United States.2 Cervical cancer 
is the most common HPV-associated cancer, but HPV also can 
cause cancer of the oropharynx, anus, penis, vagina, and vulva. 
In addition, some HPV types cause genital warts. Approximate-
ly 50% of initial HPV exposures occur during the middle to late 
teenage years;1 therefore, the 3-dose HPV vaccine is recommend-
ed routinely for all adolescents aged 11 to 12 years as part of the 
vaccine platform that includes the meningococcal conjugate vac-
cine and the tetanus, diphtheria, and pertussis vaccine (Tdap).3
 Despite recommendations, HPV vaccination coverage re-
mains low, especially compared to the other vaccines on the 
adolescent platform.4 Nationally, completion of the Tdap and 
meningococcal vaccines in 2013 was estimated at 86% and 78%, 
respectively. However, administration of at least one dose of 
the HPV vaccine (vaccine initiation) is reported at only 57% in 
females and 35% in males. HPV series completion is drastical-
ly lower at 37.6% in females and 13.9% in males. Vaccination 
rates vary substantially by geographic region within the United 
States. Among females, Kansas reported 40% coverage for HPV 
vaccine initiation (receipt of ≥ 1 HPV dose), the lowest in the 
country. For males, vaccine initiation coverage was only 25%. In 
Kansas, completion of the 3-dose series among females was 21%.
 The University of Kansas Medical Center (KUMC), lo-
cated in Kansas City (Wyandotte County), KS, is one of the 
few tertiary care centers in Kansas and serves as a major cen-
ter of healthcare for Kansas residents. There are currently no 
data on local HPV series completion at KUMC. In Wyandotte 
County, HPV series completion is estimated at about 25% for 
both males and females.5 The aim of this study was to deter-
mine vaccination coverage at KUMC for both HPV vacci-
nation initiation and HPV vaccination completion to iden-
tify baseline coverage, factors associated with series initiation 
and completion, and opportunities for local improvements. 
METHODS
 All medical records of KUMC outpatients who had at least one 
visit to KUMC in calendar year 2013 and were aged 11 or 12 years 
were reviewed. Eligible patients were seen in either the Fam-
ily Medicine and/or select Pediatric (Prairie Village, Adolescent 
Clinic, and Medical Office Building) outpatient clinics at KUMC.
 Data on HPV vaccination status and patient demograph-
ics were collected from either the visit where the first HPV 
vaccine dose was given (for all patients with at least one HPV 
vaccine dose in 2013) or the initial 2013 patient visit (for all pa-
tients without any HPV vaccine doses in 2013). Receipt of the 
other vaccines included on the adolescent platform (Tdap and 
meningococcal conjugate) was also captured. For patients who 
initiated the HPV vaccination series, additional data were re-
viewed through December 2014 to document receipt of any 
additional HPV vaccine doses. Extending the data collection 
period through December of 2014 allowed for sufficient time 
for patients to receive their second HPV vaccine dose (recom-
mended for 2 months after the initial dose) and their third HPV 
vaccine dose (recommended for 6 months after the initial dose). 
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 Initiation of the HPV vaccination series was defined as the 
proportion of the eligible population that received at least 
one dose (≥ 1 dose) of the HPV vaccine within the study time-
frame. Series completion was defined as the proportion of the 
population that received all three recommended doses of the 
HPV vaccine within the study timeframe. To evaluate pos-
sible differences in initiation and completion coverage, data 
were stratified by demographic variables (i.e., gender, race, 
ethnicity, and language spoken at home) that could be used 
to identify potential risk factors or motivators for series ini-
tiation and completion. Insurance status was not accessible 
for this project. Statistical analyses were calculated using the 
Statistical Package for the Social Sciences (SPSS). Person’s Chi-
squared tests were used to test for statistically significant dif-
ferences, with statistical significance set to a p-value of < 0.05. 
RESULTS
 Of 504 eligible patients, 51.8% were females (Table 1). 
About two-thirds of patients were non-Hispanic (68.5%), 
and charts of 80.8% showed that patients’ primary lan-
guage spoken at home was English. The most commonly 
noted race was white (38.9%), followed by black (23.2%).
TABLE 1. Demographic characteristics of study population.
Number (%) 
(n=504)
Gender
Male
Female
243 (48.2)
261 (51.8)
Race
White
Black
Other
196 (38.9)
117 (23.2)
191 (37.9)
Ethnicity
Hispanic 
Non-Hispanic
158 (31.5)
344 (68.5)
Language spoken at home
English
Spanish
Other
407 (80.8)
85 (16.9)
12 (2.4)
ASSESSING LEGISLATIVE INTEREST FOR A 
Almost three-quarters of patients (71.2%) had initiated 
the HPV vaccine series, receiving at least one HPV vaccine 
in 2013 (Figure 1). Roughly 82% of patients had received the 
other two vaccines recommended in the adolescent plat-
form, Tdap and meningococcal conjugate. Over half (55.2%) 
of patients received at least two HPV vaccines by the end of 
2014, and 39.3% of patients completed the HPV vaccine series 
(Figure 1). When stratified by gender, initiation and comple-
tion of the HPV vaccine series were very similar (Figure 1). 
Among females, 75.1% initiated the HPV vaccine, compared to 
67.1% of males (p = 0.047). Completion was 41.4% among fe-
males and 37.0% among males (p = 0.319). Completion of the 
HPV series occurred more often among Spanish-speaking fe-
males (59.5%) compared to English-speaking females (37.7%; 
p < 0.01; Table 2). Although not statistically significant, other 
noted trends included higher initiation and completion rates 
among Hispanics vs. non-Hispanics and non-whites vs. whites.
DISCUSSION 
Overall, HPV vaccination coverage at KUMC was substan-
tially better than reported vaccination coverage at the state level 
(Figure 2). Vaccination initiation among females at KUMC was 
nearly double the coverage reported for the state of Kansas 
(75.1% vs 39.9%, respectively).5 This is likewise true when com-
paring HPV vaccine initiation at KUMC to national coverage es-
timates. Based on the US Centers for Disease Control and Preven-
tion (CDC) reported data, 57.3% of females and 34.9% of males 
have at least the first HPV vaccine dose.4 Differences in cover-
age nationally, at the state level, and at KUMC also were appar-
ent for HPV vaccine completion (3 doses), though less drastic.
While small differences in the vaccination coverage between 
females and males were seen, coverage in both groups was strik-
ingly high, contrary to what has been reported previously for the 
state of Kansas and nationally.4,5 This finding suggested equal 
promotion of the HPV vaccine to males and females at KUMC, 
despite prevailing beliefs that the HPV vaccine goal is to prevent 
cervical cancer.6,7 Both state and national coverage estimates re-
flect a disparity in HPV coverage by sex; however the HPV vac-
cine has been recommended for both males and females since 
2009.3,8 KUMC performs on a similar level to the rest of the state 
and nation in regards to delivery of the Tdap vaccine, a vaccine 
long required for school admissions.4,5 The other recommended 
adolescent vaccine, meningococcal conjugate, also is delivered 
more frequently at KUMC. Overall, administration of the rec-
ommended vaccines that are part of the adolescent platform ex-
ceeds other coverage estimates, possibly indicative of a gener-
ally broad approach to adolescent vaccine delivery practiced by 
KUMC nurses and clinicians. In anecdotal observations of clini-
cal encounters conducted by the study authors, the HPV vaccine 
was recommended by the provider and presented as part of the 
adolescent platform. Provider recommendation is one of the 
main factors that can positively impact HPV vaccine uptake.9
 Despite high HPV vaccine initiation, there was a gradual de-
cline in the proportion of adolescents who received each ad-
ditional HPV dose required to complete the series. The fact 
that the HPV vaccine requires multiple doses remains a barrier 
for series completion and adequate immunologic protection.
 A two-dose series seemed to be non-inferior to a three-
dose series in the short term.10 Reducing the number of nec-
essary doses could impact HPV vaccine series completion 
positively; however, other studies are needed to evaluate 
the true long term implications of fewer HPV vaccine doses.
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Figure 1.  Vaccination coverage of recommended adolescent vaccines at KUMC, 2013.
Tdap= tetanus, diphtheria, and pertussis
Table 2. HPV vaccination coverage at KUMC by race, ethnicity and primary language spoken at home, 2013.
RACE ETHNICITY LANGUAGE
Male HPV Series Completion Male HPV Series Completion Male HPV Series Completion
Vaccine 
Status     Black    Other    White   p-value
Vaccine                          Non-
Status     Hispanic    Hispanic    p-value
Vaccine                          
Status       English        Spanish       p-value
Received ≥ 1 HPV dose Received ≥ 1 HPV dose Received ≥ 1 HPV dose
                 72.4%    72.4%    57.5%    0.059                  71.1%           65.4%          0.371                   64.6%           79.1%           0.068
Completed HPV Series Completed HPV Series Completed HPV Series
                 34.5%    42.9%     32.2%    0.292                  41.0%           35.2%           0.380                   34.9%           46.5%           0.152
Female HPV Series Completion Female HPV Series Completion Female HPV Series Completion
Vaccine 
Status     Black    Other    White   p-value
Vaccine                          Non-
Status     Hispanic    Hispanic    p-value
Vaccine                          
Status      English        Spanish         p-value
Received ≥ 1 HPV dose Received ≥ 1 HPV dose Received ≥ 1 HPV dose
                 81.4%    74.2%    72.5%    0.432                  84.0%           82.2%          0.813                    73.6%           85.7%           0.095
Completed HPV Series Completed HPV Series Completed HPV Series
                 40.7%    46.2%     37.6%    0.460                  50.7%           37.8%           0.057                    37.7%           59.5%            0.009
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Figure 2. Comparison of vaccination coverage of recommended adolescent vaccines, United States, the state of Kansas,4 and KUMC, 2013. 
Note: No data were reported for males in Kansas who completed HPV vaccination. 
KUMC = University of Kansas Medical Center
Tdap = tetanus, diphtheria, and pertussis
Mening. = meningococcal conjugate
HPV = human papillomavirus
4
 There are other trends that highlight disparities that may im-
pede vaccine series completion. National data showed higher 
HPV vaccine initiation among racial/ethnic minorities and those 
living in poverty, but higher HPV vaccine completion among 
white females and males and patients of higher socioeconomic 
status.11 At KUMC, both higher initiation and completion rates 
were observed among minority populations, an important find-
ing due to higher morbidity and mortality of HPV-associated 
cancers in these groups.12-14 Barriers to vaccine completion, such 
as the added costs associated with extra appointments (i.e., 
transportation, etc.)11 or youth not visiting a provider for a well-
child visit may not be as prevalent among the population at 
KUMC, where the majority of the patient population consists of 
underserved ethnic/racial minorities who need to be seen for an 
annual well-child visit as a requirement for receiving Medicaid. 
   Vaccine receipt data for this study were collected from re-
views of patient charts maintained at KUMC, which may not 
capture vaccine delivery at other institutions. Such underreport-
ing would result in lower calculated HPV vaccine coverage than 
was present. In addition, calculated KUMC vaccination rates 
potentially could be higher than those reported here if patients 
were followed for a longer period of time. However, to follow 
the HPV vaccine delivery schedule recommended by CDC, 
follow-up was limited to one year. Limited chart access led to 
only a few demographic variables being assessed. Possibly im-
portant variables, like insurance status, may play a role in vac-
cination success in the KUMC population. While the findings 
presented are not generalizable to other locations, these data 
showed that higher coverage of all three recommended ado-
lescent vaccines can be achieved in a busy, urban clinic setting. 
While HPV vaccine initiation and completion at KUMC are sig-
nificantly higher than expected based on previously reported na-
tional and state data, there is a need for improvement to achieve the 
minimum 80% vaccination level recommended by the Advisory 
Committee on Immunization Practices (ACIP).3 Further studies 
are needed to evaluate practices at KUMC, including identifying 
effective approaches to increase HPV vaccine series completion. 
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